Lafayette, R. Et Al. 2024. A plain language summary of the NefIgArd trial: Nefecon for the treatment of patients with immunoglobulin A nephropathy. Future Rare Diseases , vol.4, no.1 .

Lafayette, R., Kristensen, J., Stone, A., Floege, J., Tesař, V., Trimarchi, H., ... Zhang, H.(2024). A plain language summary of the NefIgArd trial: Nefecon for the treatment of patients with immunoglobulin A nephropathy. Future Rare Diseases , vol.4, no.1.

Lafayette, Richard Et Al. "A plain language summary of the NefIgArd trial: Nefecon for the treatment of patients with immunoglobulin A nephropathy," Future Rare Diseases , vol.4, no.1, 2024

Lafayette, Richard Et Al. "A plain language summary of the NefIgArd trial: Nefecon for the treatment of patients with immunoglobulin A nephropathy." Future Rare Diseases , vol.4, no.1, 2024

Lafayette, R. Et Al. (2024) . "A plain language summary of the NefIgArd trial: Nefecon for the treatment of patients with immunoglobulin A nephropathy." Future Rare Diseases , vol.4, no.1.

@article{article, author={Richard Lafayette Et Al. }, title={A plain language summary of the NefIgArd trial: Nefecon for the treatment of patients with immunoglobulin A nephropathy}, journal={Future Rare Diseases}, year=2024}